Physician profile
Gregg F Gerety
NPI 1881691152
$345,258.24
in general payments reported to CMS, 2019-2025
38 companies · $31K in 2025
The $31K reported for 2025 was more than what 94% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135K · 2020: $60K · 2021: $42K · 2022: $38K · 2023: $31K · 2024: $8,170 · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $55K · Travel and Lodging: $11K · Food and Beverage: $4,048 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $650 · Gift: $59.40 · Education: $56.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $54,769.00 |
| Travel and Lodging | $10,647.41 |
| Food and Beverage | $4,048.30 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $650.00 |
| Gift | $59.40 |
| Education | $56.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $143,593.35 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Lilly USA, LLC | $133,674.24 | 2019-2023 | Trulicity, Jardiance, Lyumjev |
| Novo Nordisk INC | $57,384.31 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Janssen Pharmaceuticals, INC | $3,069.85 | 2019-2020 | |
| Eli Lilly and Company | $1,238.66 | 2019 | |
| Novo Nordisk As | $924.99 | 2019 | |
| Amgen INC. | $818.50 | 2019-2025 | Evenity, Tepezza, Prolia |
| Abbott Laboratories | $767.30 | 2019-2025 | Freestyle Libre 3 |
| Insulet Corporation | $751.49 | 2019-2023 | Omnipod |
| Sanofi-Aventis U.S. LLC | $437.89 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $396.28 | 2019-2022 | |
| Abbvie INC. | $334.54 | 2019-2025 | |
| Mannkind Corporation | $245.00 | 2019-2024 | Afrezza |
| Medtronic, INC. | $180.32 | 2023 | Minimed 780g |
| Ipsen Biopharmaceuticals, INC | $167.78 | 2019-2023 | Somatuline Depot |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregg Gerety listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.